Glycemic Index Laboratories, Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Los Angeles CA United States (2010)

Organization Overview

First Clinical Trial
2010
NCT00801814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

GI Labs | Glycemic Index Laboratories, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

polyglycoplex (2 trials)

Drugs in Phase 2 Trials (1)

beta-glucans (1 trial)

Drugs in Phase 1 Trials (2)

amivantamab-vmjw (Rybrevant) (1 trial)

HP-211 (1 trial)

Drugs in Other Trials (10)

amioca starch (1 trial)

calcium propionate (1 trial)

fiber (1 trial)

glucose (1 trial)

lentil (1 trial)

oat bran (1 trial)

oatmeal (1 trial)

oryza sativa (1 trial)

potato (1 trial)

sc-fos (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypercholesterolemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 14